N-Acetylcysteine and Safranal Prevented the Brain Damage Induced by Hyperthyroidism in Adult Male Rats
Overview
Nutritional Sciences
Affiliations
Hyperthyroidism is associated with impairment in the neurotransmission and severe tissue damage in the brain. The present study explored the potential deleterious effects of experimentally-induced hyperthyroidism on the neurotransmitters, oxidative homeostasis, apoptosis and DNA fragmentation in cerebral cortex, thalamus & hypothalamus, and hippocampus in rats. The ameliorative effects of N-acetylcysteine (NAC; 50 mg/kg, oral) and safranal (50 mg/kg, intraperitoneal) against hyperthyroidism (L-T4 500 µg/kg, subcutaneous) were investigated. All treatments continued daily over three weeks. Hyperthyroidism was manifested by significant elevations in serum fT3 and fT4 levels and a decline in serum TSH level and body weight. It was also characterized by significant elevations in the levels of dopamine, serotonin, and 5-hydroxyindole acetic acid, and monoamine oxidase activity to varying degrees in the brain regions examined and a significant reduction in norepinephrine in hippocampus only. Hyperthyroidism resulted in a significant oxidative stress in brain typified by elevations in malondialdehyde and nitric oxide content and reductions in glutathione level and SOD and catalase activities. This led to elevations in Caspases 9 and 3 and a reduction in Bcl2 resulting in DNA damage and confirmed by the histopathology of brain tissue. The administration of NAC or safranal with L-T4 prevented these deleterious effects by reducing the oxidative load and improving the brain antioxidant status. Hyperthyroidism disrupted the neurotransmitters in the brain which aggravated the oxidative stress and resulted in apoptosis. N-Acetylcysteine and safranal prevented these deleterious effects by enhancing the poor antioxidant milieu of the brain.
Ahmed D, El-Beih N, El-Hussieny E, El-Sayed W Biol Trace Elem Res. 2024; .
PMID: 39134772 DOI: 10.1007/s12011-024-04330-1.
Shehata N, Abd El-Salam D, Hussein R, Rizk S PLoS One. 2023; 18(11):e0293660.
PMID: 37910529 PMC: 10619823. DOI: 10.1371/journal.pone.0293660.
Pharmacological effects of Safranal: An updated review.
Esmaealzadeh D, Moodi Ghalibaf A, Shariati Rad M, Rezaee R, Razavi B, Hosseinzadeh H Iran J Basic Med Sci. 2023; 26(10):1131-1143.
PMID: 37736506 PMC: 10510479. DOI: 10.22038/IJBMS.2023.69824.15197.
Purinergic signaling in thyroid disease.
Le Y, Lu D, Xue M Purinergic Signal. 2022; 19(1):221-227.
PMID: 35347568 PMC: 9984614. DOI: 10.1007/s11302-022-09858-2.
Mohammed N, Ahmed S, Hegazy N, Kashishy K Toxicol Res (Camb). 2021; 10(5):992-1002.
PMID: 34733484 PMC: 8557673. DOI: 10.1093/toxres/tfab083.